Treatment
Etoposide clinical trials
We’re tracking 154 recruiting studies that include Etoposide, each written for real people, not researchers, below.
Recruiting studies
- NCT06418087RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
Bologna, BOAges 18 years+ - NCT07843940RecruitingPhase 1/Phase 2
Two study drugs for extensive-stage small cell lung cancer
This trial tests two new immunotherapy drugs (obrixtamig and pumitamig) given together for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and helps shrink or control the cancer.
Miami, FloridaAges 18 years+ - NCT07847190RecruitingPhase 2
Adding paclitaxel to standard chemotherapy for tough testicular cancer
This trial tests if adding a drug called paclitaxel to the standard chemotherapy combination (BEP) can improve outcomes for people with aggressive testicular cancer. It is for those whose tumor markers did not drop as fast as expected after the first round of chemo.
MoscowAges 16 years+ - NCT06464068RecruitingPhase 2
Immunotherapy plus chemo for first-line advanced extrapulmonary small cell cancer
This trial tests a new combination of durvalumab (an immunotherapy) plus standard chemotherapy for people with advanced small cell carcinoma that started outside the lung and has not been treated before. The goal is to see if this combo works better than chemo alone.
Reggio EmiliaAges 18 years+ - NCT06110572RecruitingPhase 1/Phase 2
Total body irradiation with immunotherapy for extensive SCLC
This trial adds total body irradiation (a low dose of radiation to the whole body) to standard atezolizumab (immunotherapy) plus chemotherapy for people with extensive-stage small cell lung cancer. The goal is to see if the radiation helps the immunotherapy work better.
Nashville, TennesseeAges 18 years+ - NCT06489808RecruitingPhase 2
Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06520176RecruitingPhase 3
Comparing two stem cell collection methods for multiple myeloma
This study tests two different combinations of medicines to help collect stem cells for a transplant in people newly diagnosed with multiple myeloma. The goal is to see which approach works better and is safer for you.
Dongyang, ZhejiangAges 18–75 - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT04638790RecruitingPhase 3
First treatment chemotherapy study for newly diagnosed Hodgkin lymphoma
This trial studies the best first chemotherapy approach for people newly diagnosed with classical Hodgkin lymphoma. It may help improve outcomes by comparing how treatment is given in routine care settings in Russia.
Mumbai, Opd-81 Main Building, Dr. E Borges Road, Parel 400012Ages 18–50 - NCT07739758RecruitingPhase 3
Study of two drugs for newly diagnosed extensive-stage small cell lung cancer
This trial tests a new combination of two drugs (YL201 and serplulimab) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the combination helps shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07625644RecruitingPhase 3
New immunotherapy combination for advanced lung cancer
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
Springdale, ArkansasAges 18 years+ - NCT07583511RecruitingPhase 2
New drug combination for advanced lung cancer
This study tests whether a combination of three drugs—teniposide, cisplatin, and serplulimab—can effectively treat extensive-stage small cell lung cancer (a fast-growing type of lung cancer that has spread). Serplulimab is an immunotherapy drug designed to help your immune system fight cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07583550RecruitingPhase 2
Low-dose radiation followed by immunotherapy for extensive small cell lung cancer
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
Jiangmen, GuangdongAges 18–75 - NCT06756152RecruitingPhase 2/Phase 3
Preventing GVHD after transplant for blood cancers in children and young adults
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
MoscowAges 1 day–21 years - NCT06480864Recruiting
Study of adebelimumab and apatinib for extensive stage small cell lung cancer maintenance
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
Shenyang, LiaoningAges 18 years+ - NCT07502300RecruitingPhase 3
New drug combo for advanced small cell lung cancer
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
Zhengzhou, HenanAges 18 years+ - NCT07498959Recruiting
Surgery vs. chemo for testicular cancer that has spread
This study compares two standard treatments—surgery to remove lymph nodes in the abdomen (RPLND) versus chemotherapy—for men with testicular cancer that has spread to a small area in the abdomen. The goal is to see which approach works better and has fewer side effects.
Gothenburg, GöteborgAges 18 years+ - NCT06769971RecruitingPhase 2
Ivonescimab and cadonilimab plus chemo for extensive-stage small cell lung cancer
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
Chengdu, SichuanAges 18–75 - NCT07481669RecruitingPhase 2
Stem cell transplant for lymphoma at high risk of brain relapse
This trial tests a stem cell transplant with a special chemo combination (TEAM) to see if it can prevent lymphoma from coming back in the brain or spinal cord for people with high-risk non-Hodgkin lymphoma.
Hangzhou, ZhejiangAges 18–70 - NCT06780826Recruiting
Atezolizumab plus chemo for extensive-stage small cell lung cancer
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
ShanghaiAges 18 years+ - NCT07381829RecruitingPhase 1
HC010 plus chemotherapy for advanced lung cancer
This trial tests an experimental drug called HC010 combined with chemotherapy for people with advanced lung cancer, including certain types of non-small cell or small cell lung cancer. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07336147RecruitingPhase 2
Immunotherapy, chemo, and radiation for cervical cancer
This study tests a combination of immunotherapy (dostarlimab), chemotherapy (cisplatin and etoposide), and radiation to treat small cell neuroendocrine cervical cancer. The goal is to see if this approach works better and is safe for people who haven't had treatment yet.
Taoyuan, TaiwanAges 20–70 - NCT06869239Recruiting
Predicting response to PD-L1 inhibitor after chemoradiotherapy for limited-stage small cell lung cancer
This study uses a blood test to see if it can predict how well the PD-L1 inhibitor (an immunotherapy drug) works after standard chemotherapy and radiation for limited-stage small cell lung cancer. It aims to find better ways to match treatment to patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT07321912RecruitingPhase 2
Eflornithine (DFMO) for Ewing sarcoma and osteosarcoma
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
Tampa, FloridaAges birth–50 years
Common questions
- Are there clinical trials studying Etoposide?
- Yes. Clin2 currently lists 154 recruiting studies that include Etoposide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Etoposide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Etoposide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Etoposide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.